Alnylam's Phase 2 ALN-4324 study in type 2 diabetes is active, not recruitingNov 13Trial updateALN-4324Alnylam Pharmaceuticals
Alnylam authorizes $1 billion stock buyback, announces commercial chief's departureNov 5PeopleAlnylam Pharmaceuticals
Alnylam posts Q3 2026 results, widens nucresiran trial, advances Huntington's programOct 29Quarterly updateAlnylam Pharmaceuticalsnucresiran
Alnylam's Phase 1 trial of ALN-4915 in healthy volunteers is active, not recruitingOct 15Trial updateALN-4915Alnylam Pharmaceuticals
Alnylam cuts 2026 TTR revenue outlook, advances Alzheimer's and rare disease pipelineJul 30Quarterly updateAlnylam Pharmaceuticals